ADVM:NSD-Adverum Biotechnologies, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.86

Change

0.00 (0.00)%

Market Cap

USD 0.87B

Volume

1.08M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD68.41B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD56.78B 21.32 15.54
REGN Regeneron Pharmaceuticals, Inc

N/A

USD53.84B 16.47 12.24
BNTX BioNTech SE

N/A

USD36.60B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD36.16B 60.18 35.79
BGNE BeiGene, Ltd

N/A

USD28.44B N/A N/A
SGEN Seagen Inc

N/A

USD26.38B 43.18 34.88
RPRX Royalty Pharma plc

N/A

USD25.42B 22.60 15.19
GMAB Genmab A/S

N/A

USD22.94B 26.59 3.31
CVAC CureVac N.V

N/A

USD20.43B N/A N/A

ETFs Containing ADVM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.27% 27% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.27% 27% F 12% F
Trailing 12 Months  
Capital Gain -31.37% 17% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.37% 17% F 5% F
Trailing 5 Years  
Capital Gain 60.22% 69% D+ 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.22% 69% D+ 52% F
Average Annual (5 Year Horizon)  
Capital Gain 60.37% 81% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.37% 81% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 79.45% 37% F 20% F
Risk Adjusted Return 75.98% 93% A 87% B+
Market Capitalization 0.87B 68% D+ 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.06 85% B 65% D
Price / Cash Flow Ratio -10.94 60% D- 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -38.57% 69% D+ 27% F
Return on Invested Capital -39.07% 62% D- 21% F
Return on Assets -20.90% 61% D- 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 13.40 6% F 2% F
Short Percent 12.60% 23% F 16% F
Beta 1.46 46% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector